Jaypirca

Eli Lilly’s Jaypirca to dominate CLL BTK inhibitor market by 2032
Biopharma Reporter
Thu, 01/18/24 - 05:04 pm
Eli Lilly
Jaypirca
CLL
Btk inhibitors
Lilly Wins Second Accelerated Approval for Reversible BTK Inhibitor
BioSpace
Mon, 12/4/23 - 09:41 am
Eli Lilly
FDA
Jaypirca
CLL
small lymphocytic leukemia
Btk inhibitors
Lilly enters ripe BTK field with quick FDA nod in mantle cell lymphoma
Endpoints
Sun, 01/29/23 - 02:14 pm
Eli Lilly
Btk inhibitors
FDA
Merck
mantle cell lymphoma
Jaypirca